Post-infectious immune suppression: A new paradigm of severe infections

Medecine et Maladies Infectieuses

Volumn 44, Issue 10, 2014, Pages 455-463

  Grimaldi, D ^a,b   Llitjos, J F ^b   Pene F ^b,c,d  

^a CENTRE HOSPITALIER DE VERSAILLES   (France)

^b INSTITUT COCHIN   (France)

^c Inserm U1016 ^*  (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Immunotherapy; Influenza; Sepsis induced immunosuppression; Severe sepsis; Superinfection

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 7; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PNEUMOCOCCUS VACCINE; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 LIGAND 1 ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR; PROGRAMMED DEATH 1 RECEPTOR ANTIBODY; PROTEIN ANTIBODY; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; APOPTOSIS; BACTEREMIA; BACTERIAL SUPERINFECTION; BONE MARROW CELL; CANDIDEMIA; CELL EXPANSION; CELL INTERACTION; CYTOKINE PRODUCTION; DENDRITIC CELL; DISEASE ASSOCIATION; DISEASE SEVERITY; EPIDEMIC; HOSPITAL INFECTION; HOST PATHOGEN INTERACTION; HOST RESISTANCE; HUMAN; IDIOPATHIC DISEASE; IMMUNE DEFICIENCY; IMMUNE DYSREGULATION; IMMUNOMODULATION; IMMUNOREGULATION; IMMUNOSTIMULATION; INFECTION; INFECTION PREVENTION; INFECTION RISK; INFECTION SENSITIVITY; INFLAMMATION; INNATE IMMUNITY; INTENSIVE CARE UNIT; LUNG INJURY; LYMPHOCYTOPENIA; NONHUMAN; REVIEW; SEASONAL INFLUENZA; SEPSIS; STAPHYLOCOCCAL PNEUMONIA; SUPPRESSOR CELL; TRANSLATIONAL RESEARCH; CROSS INFECTION; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; INFLUENZA, HUMAN; LUNG DISEASE; RISK FACTOR; SEVERITY OF ILLNESS INDEX;

CROSS INFECTION; HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA, HUMAN; INTENSIVE CARE UNITS; LUNG DISEASES; RISK FACTORS; SEPSIS; SEVERITY OF ILLNESS INDEX;

EID: 84908176272     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2014.07.017     Document Type: Review

References (50)

1. Chertow D.S., Memoli M.J. Bacterial coinfection in influenza: a grand rounds review. JAMA 2013, 309:275-282.
2. Hotchkiss R.S., Monneret G., Payen D. Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis 2013, 13:260-268.
3. Hotchkiss R.S., Nicholson D.W. Apoptosis and caspases regulate death and inflammation in sepsis. Nat Rev Immunol 2006, 6:813-822.
4. Wheeler D.S., Lahni P.M., Denenberg A.G., Poynter S.E., Wong H.R., Cook J.A., et al. Induction of endotoxin tolerance enhances bacterial clearance and survival in murine polymicrobial sepsis. Shock 2008, 30:267-273.
5. Michelow I.C., Olsen K., Lozano J., Rollins N.K., Duffy L.B., Ziegler T., et al. Epidemiology and clinical characteristics of community-acquired pneumonia in hospitalized children. Pediatrics 2004, 113:701-707.
6. McCullers J.A. The co-pathogenesis of influenza viruses with bacteria in the lung. Nat Rev Microbiol 2014, 12:252-262.
7. Metzger D.W., Sun K. Immune dysfunction and bacterial coinfections following influenza. J Immunol 2013, 191:2047-2052.
8. Li W., Moltedo B., Moran T.M. Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of gammadelta T cells. J Virol 2012, 86:12304-12312.
9. Shahangian A., Chow E.K., Tian X., Kang J.R., Ghaffari A., Liu S.Y., et al. Type I IFNs mediate development of postinfluenza bacterial pneumonia in mice. J Clin Invest 2009, 119:1910-1920.
10. Sun K., Metzger D.W. Influenza infection suppresses NADPH oxidase-dependent phagocytic bacterial clearance and enhances susceptibility to secondary methicillin-resistant Staphylococcus aureus infection. J Immunol 2014, 192:3301-3307.
11. Brun-Buisson C., Richard J.C., Mercat A., Thiebaut A.C., Brochard L. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 2011, 183:1200-1206.
12. Otto G.P., Sossdorf M., Claus R.A., Rodel J., Menge K., Reinhart K., et al. The late phase of sepsis is characterized by an increased microbiological burden and death rate. Crit Care 2011, 15:R183.
13. Bouadma L., Deslandes E., Lolom I., Le Corre B., Mourvillier B., Regnier B., et al. Long-term impact of a multifaceted prevention program on ventilator-associated pneumonia in a medical intensive care unit. Clin Infect Dis 2010, 51:1115-1122.
14. Landelle C., Lepape A., Francais A., Tognet E., Thizy H., Voirin N., et al. Nosocomial infection after septic shock among intensive care unit patients. Infect Control Hosp Epidemiol 2008, 29:1054-1065.
15. Tortorano A.M., Dho G., Prigitano A., Breda G., Grancini A., Emmi V., et al. Invasive fungal infections in the intensive care unit: a multicentre, prospective, observational study in Italy (2006-2008). Mycoses 2012, 55:73-79.
16. Limaye A.P., Kirby K.A., Rubenfeld G.D., Leisenring W.M., Bulger E.M., Neff M.J., et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008, 300:413-422.
17. Luyt C.E., Combes A., Deback C., Aubriot-Lorton M.H., Nieszkowska A., Trouillet J.L., et al. Herpes simplex virus lung infection in patients undergoing prolonged mechanical ventilation. Am J Respir Crit Care Med 2007, 175:935-942.
18. Osuchowski M.F., Welch K., Siddiqui J., Remick D.G. Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol 2006, 177:1967-1974.
19. Couper K.N., Blount D.G., Riley E.M. IL-10: the master regulator of immunity to infection. J Immunol 2008, 180:5771-5777.
20. van Dissel J.T., van Langevelde P., Westendorp R.G., Kwappenberg K., Frolich M. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998, 351:950-953.
21. Cavaillon J.M., Adib-Conquy M. Monocytes/macrophages and sepsis. Crit Care Med 2005, 33:S506-S509.
22. Venet F., Lukaszewicz A.C., Payen D., Hotchkiss R., Monneret G. Monitoring the immune response in sepsis: a rational approach to administration of immunoadjuvant therapies. Curr Opin Immunol 2013, 25:477-483.
23. Pene F., Courtine E., Ouaaz F., Zuber B., Sauneuf B., Sirgo G., et al. Toll-like receptors 2 and 4 contribute to sepsis-induced depletion of spleen dendritic cells. Infect Immun 2009, 77:5651-5658.
24. Boomer J.S., To K., Chang K.C., Takasu O., Osborne D.F., Walton A.H., et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011, 306:2594-2605.
25. Benjamim C.F., Lundy S.K., Lukacs N.W., Hogaboam C.M., Kunkel S.L. Reversal of long-term sepsis-induced immunosuppression by dendritic cells. Blood 2005, 105:3588-3595.
26. Pene F., Zuber B., Courtine E., Rousseau C., Ouaaz F., Toubiana J., et al. Dendritic cells modulate lung response to pseudomonas aeruginosa in a murine model of sepsis-induced immune dysfunction. J Immunol 2008, 181:8513-8520.
27. Grimaldi D., Louis S., Pene F., Sirgo G., Rousseau C., Claessens Y.E., et al. Profound and persistent decrease of circulating dendritic cells is associated with ICU-acquired infection in patients with septic shock. Intensive Care Med 2011, 37:1438-1446.
28. Venet F., Filipe-Santos O., Lepape A., Malcus C., Poitevin-Later F., Grives A., et al. Decreased T-cell repertoire diversity in sepsis: a preliminary study. Crit Care Med 2013, 41:111-119.
29. Kushwah R., Oliver J.R., Zhang J., Siminovitch K.A., Hu J. Apoptotic dendritic cells induce tolerance in mice through suppression of dendritic cell maturation and induction of antigen-specific regulatory T cells. J Immunol 2009, 183:7104-7118.
30. Venet F., Chung C.S., Kherouf H., Geeraert A., Malcus C., Poitevin F., et al. Increased circulating regulatory T cells (CD4(+)CD25 (+)CD127 (-)) contribute to lymphocyte anergy in septic shock patients. Intensive Care Med 2009, 35:678-686.
31. Nascimento D.C., Alves-Filho J.C., Sonego F., Fukada S.Y., Pereira M.S., Benjamim C., et al. Role of regulatory T cells in long-term immune dysfunction associated with severe sepsis. Crit Care Med 2010, 38:1718-1725.
32. Grimaldi D., Le Bourhis L., Sauneuf B., Dechartres A., Rousseau C., Ouaaz F., et al. Specific MAIT cell behaviour among innate-like T lymphocytes in critically ill patients with severe infections. Intensive Care Med 2014, 40:192-201.
33. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009, 9:162-174.
34. Delano M.J., Scumpia P.O., Weinstein J.S., Coco D., Nagaraj S., Kelly-Scumpia K.M., et al. MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med 2007, 204:1463-1474.
35. Deng J.C., Cheng G., Newstead M.W., Zeng X., Kobayashi K., Flavell R.A., et al. Sepsis-induced suppression of lung innate immunity is mediated by IRAK-M. J Clin Invest 2006, 116:2532-2542.
36. Hoogerwerf J.J., Leendertse M., Wieland C.W., de Vos A.F., de Boer J.D., Florquin S., et al. Loss of suppression of tumorigenicity 2 (ST2) gene reverses sepsis-induced inhibition of lung host defense in mice. Am J Respir Crit Care Med 2011, 183:932-940.
37. Pene F., Grimaldi D., Zuber B., Sauneuf B., Rousseau C., El Hachem C., et al. Toll-like receptor 2 deficiency increases resistance to Pseudomonas aeruginosa pneumonia in the setting of sepsis-induced immune dysfunction. J Infect Dis 2012, 206:932-942.
38. Davis C.G., Chang K., Osborne D., Walton A.H., Ghosh S., Dunne W.M., et al. TLR3 agonist improves survival to secondary pneumonia in a double injury model. J Surg Res 2013, 182:270-276.
39. Roquilly A., Gautreau L., Segain J.P., de Coppet P., Sebille V., Jacqueline C., et al. CpG-ODN and MPLA prevent mortality in a murine model of post-hemorrhage-Staphyloccocus aureus pneumonia. PloS one 2010, 5:e13228.
40. Seok J., Warren H.S., Cuenca A.G., Mindrinos M.N., Baker H.V., Xu W., et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A 2013, 110:3507-3512.
41. D'Arpa N., Accardo-Palumbo A., Amato G., D'Amelio L., Pileri D., Cataldo V., et al. Circulating dendritic cells following burn. Burns 2009, 35:513-518.
42. Roquilly A., Braudeau C., Cinotti R., Dumonte E., Motreul R., Josien R., et al. Impaired blood dendritic cell numbers and functions after aneurysmal subarachnoid hemorrhage. PloS one 2013, 8:e71639.
43. Lukaszewicz A.C., Grienay M., Resche-Rigon M., Pirracchio R., Faivre V., Boval B., et al. Monocytic HLA-DR expression in intensive care patients: interest for prognosis and superinfection prediction. Crit Care Med 2009, 37:2746-2752.
44. Hornef M.W., Wick M.J., Rhen M., Normark S. Bacterial strategies for overcoming host innate and adaptive immune responses. Nat Immunol 2002, 3:1033-1040.
45. Leentjens J., Kox M., Koch R.M., Preijers F., Joosten L.A., van der Hoeven J.G., et al. Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-controlled, randomized pilot study. Am J Respir Crit Care Med 2012, 186:838-845.
46. Broughton S.E., Dhagat U., Hercus T.R., Nero T.L., Grimbaldeston M.A., Bonder C.S., et al. The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand recognition to initiation of signaling. Immunol Rev 2012, 250:277-302.
47. Meisel C., Schefold J.C., Pschowski R., Baumann T., Hetzger K., Gregor J., et al. Granulocyte-macrophage colony-stimulating factor to reverse sepsis-associated immunosuppression: a double-blind, randomized, placebo-controlled multicenter trial. Am J Respir Crit Care Med 2009, 180:640-648.
48. Chang K.C., Burnham C.A., Compton S.M., Rasche D.P., Mazuski R., Smcdonough J., et al. Blockade ofthe negative co-stimulatory molecules PD-1 and CTLA-4 improves survival in primary and secondary fungal sepsis. Crit Care 2013, 17:R85.
49. Chang K., Svabek C., Vazquez-Guillamet C., Sato B., Rasche D., Wilson S., et al. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care 2014, 18:R3.
50. Cavaillon J.M., Eisen D., Annane D. Is boosting the immune system in sepsis appropriate?. Crit Care 2014, 18:216.